Background: There is little data regarding the risk of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a prior history of cancer who are exposed to ustekinumab or vedolizumab. We assessed the risk of subsequent cancer in patients exposed to these agents.
Methods: We performed a retrospective cohort study of patients with IBD and a history of cancer at an academic medical center between January 2013 and December 2020.